Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Cell Proliferation and Viability Assay

Sygnature Discovery has adopted a broad range of techniques to help you to identify biologically active compounds that underline the consequences of target inactivation on cell proliferation, activation, apoptosis or cytotoxic cell death.

Cell Proliferation and Viability Assay

Cell proliferation and viability assays are powerful tools facilitating discovery of novel therapeutics. Most in vitro proliferation assays determine the number of viable cells and are based on quantifying the number of cell nuclei, metabolic activity, assessing cell redox potential or mitochondrial integrity. These proliferation assays can be multiplexed with cytotoxicity or apoptosis assays that monitor cell fate in response to compound treatment. Compound-induced cell apoptosis can be measured by an increase in cell membrane permeability, loss of membrane asymmetry or caspases activation. We rely on automated liquid handling to allow high-throughput data acquisition. This helps us to quickly validate compounds and facilitate selection for the next screening round within a Design-Make-Test-Analyse cycle. These cell proliferation and viability methods can be applied to both Phenotypic and target-based drug discovery projects. We utilize, for example:

  • Peripheral blood mononuclear cells (PBMCs) obtained from our Blood Donor Panel
  • Primary cell populations or subpopulations (T cells, B cells, Natural Killer cells, macrophages)

Techniques used to measure cell proliferation, viability and apoptosis include:

  • Detection of cell’s metabolic activity
    • Resazurin reduction
    • ATP luciferase coupled reaction
  • Quantification of cell nuclei or cell confluency
    • Fluorescent labelling of DNA/cell nuclei
    • Acquisition of phase contrast images of cells using IncuCyte® ZOOM
  • Detection of actively dividing cells
    • BrdU incorporation into newly synthesized DNA
  • Cell apoptosis/cytotoxicity
    • Caspase 3/7 activation during cell apoptosis
    • Increase in cell membrane permeability
    • Loss in cell membrane asymmetry by detection of exposed phosphatidylserine on cell surface

Examples of in vitro assays to measure cell proliferation, viability and apoptosis.

Cell Viability & Proliferation Assay Development

Figure A: Resazurin assay using cells treated with two compounds. Compounds display different potency on proliferation of cells.

Cell Viability & Proliferation Assay Development

Figure B: ATP Luciferase coupled assay. Compounds display different potency on proliferation of wild-type versus knock-out cells.

Cell Viability & Proliferation Assay Development

Figure C: BrdU incorporation assay with PMBCs that were left unstimulated or stimulated with PHA in the presence of selected compound. The compound reduces activation and proliferation of T-cells responding to stimulus.

Cell proliferation and Viability

Figure D: Caspase 3/7 Glo® activities in cells treated with a compound. Data expressed in comparison to CellTiter Glo® to demonstrate correlation between a reduction in cell viability with an increase in caspase 3/7 activation.

Cell Viability & Proliferation Assay Development

Figure E: Real-time cell confluency assessment using the IncuCyte® ZOOM instrument. Data display a time-dependent increase in cell confluency in response to stimulation.

Figure F: Detection of cytotoxicity and apoptosis in cells treated with a compound. Data shows dose-dependent increase in CellTox Green® intracellular accumulation and Annexin V binding in response to compound treatment.

Figure G: Determination of compound effect on cell growth. The graph shows a compound that is cytotoxic (X), anti-proliferative (Y) or cytostatic (Z).

Latest News

View All

Sygnature Discovery and Daewoong Pharma announce research…

New platform set to accelerate early-stage targeted…

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…